Keywords: Roche, Evotec, NR2B, Depression, Terminate study

Roche and Evotec terminate Ph II study with NR2B in treatment-resistant depression

Article | 20 May 2011

Print This

German biotech firm Evotec AG (Xetra: EVT) and Swiss drug major Roche (SIX: ROG) say they have decided to voluntarily ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in